PCLO — Pharmacielo Income Statement
0.000.00%
- CA$16.90m
- CA$37.28m
- CA$1.54m
Annual income statement for Pharmacielo, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.787 | 2.65 | 1.95 | 5.31 | 1.54 |
Cost of Revenue | |||||
Gross Profit | -0.114 | -5.04 | -3.07 | 1.59 | -1.88 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 35 | 47.3 | 27.1 | 18 | 15.4 |
Operating Profit | -34.2 | -44.6 | -25.2 | -12.7 | -13.9 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -34.7 | -43.8 | -26.6 | -14.5 | -16.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -34.7 | -43.8 | -26.6 | -14.5 | -16.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -34.7 | -43.8 | -26.6 | -14.5 | -16.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -34.7 | -43.8 | -26.6 | -14.5 | -16.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.343 | -0.363 | -0.174 | -0.082 | -0.081 |